Want to see IN:PAR full AI Analyst Report?
PAR Stock Chart & Stats
₹100.93
-₹2.28(-1.11%)
At close: 4:00 PM EST
₹100.93
-₹2.28(-1.11%)
Day’s Range― - ―
52-Week Range₹78.05 - ₹180.00
Previous CloseN/A
Volume42.53K
Average Volume (3M)17.22K
Market Cap
₹1.30B
Enterprise Value₹548.47M
Total Cash (Recent Filing)₹418.43M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)8.9
Beta0.88
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.7%
Share Statistics
EPS (TTM)11.78
Shares Outstanding12,304,636
10 Day Avg. Volume8,818
30 Day Avg. Volume17,222
Financial Highlights & Ratios
PEG Ratio-3.82
Price to Book (P/B)0.86
Price to Sales (P/S)0.93
P/FCF Ratio6.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free structure materially reduces financial risk and interest burden, preserving cash for operations and investment. It also gives Par Drugs greater flexibility to manage weaker periods, support growth initiatives, and withstand changes in financing conditions over the next several quarters.
Positive Cash GenerationPositive free cash flow indicates that the business has generally converted operations into internally generated funding. This supports reinvestment, working-capital needs, and financial resilience without relying on debt, although the strength of conversion varies between reporting periods.
Healthy ProfitabilityA double-digit net margin provides an established earnings base and suggests the company retains meaningful profit after costs. Sustained profitability can fund expansion and strengthen resilience, while also giving management room to respond to changing product mix and market conditions.
Bears Say
Inconsistent Revenue GrowthUneven revenue growth makes the pace of business expansion less predictable and complicates capacity, inventory, and investment planning. The return to stronger growth is encouraging, but the prior slowdown indicates that demand expansion has not yet been consistently durable.
Margin CompressionMargin compression can reduce earnings growth even when revenue continues to rise, limiting operating leverage and internal funding capacity. If the lower margin level persists, Par Drugs may have less flexibility to absorb cost pressure or invest while maintaining profitability.
Gross-margin VolatilityVariable gross margins make future earnings quality harder to forecast because profitability depends on changing costs and product mix. This can produce uneven operating performance and makes sustained margin improvement less certain over the next several reporting periods.
Par Drugs and Chemicals Limited News
PAR FAQ
What was Par Drugs and Chemicals Limited’s price range in the past 12 months?
Par Drugs and Chemicals Limited lowest stock price was ₹78.05 and its highest was ₹180.00 in the past 12 months.
What is Par Drugs and Chemicals Limited’s market cap?
Par Drugs and Chemicals Limited’s market cap is ₹1.30B.
When is Par Drugs and Chemicals Limited’s upcoming earnings report date?
Par Drugs and Chemicals Limited’s upcoming earnings report date is Nov 11, 2026 which is in 20 days.
How were Par Drugs and Chemicals Limited’s earnings last quarter?
Par Drugs and Chemicals Limited released its earnings results on Aug 08, 2026. The company reported ₹3.83 earnings per share for the quarter.
Is Par Drugs and Chemicals Limited overvalued?
According to Wall Street analysts Par Drugs and Chemicals Limited’s price is currently Overvalued.
Does Par Drugs and Chemicals Limited pay dividends?
Par Drugs and Chemicals Limited pays a Notavailable dividend of ₹1.25 which represents an annual dividend yield of 0.7%. See more information on Par Drugs and Chemicals Limited dividends here
What is Par Drugs and Chemicals Limited’s EPS estimate?
Par Drugs and Chemicals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Par Drugs and Chemicals Limited have?
Par Drugs and Chemicals Limited has 12,304,636 shares outstanding.
What happened to Par Drugs and Chemicals Limited’s price movement after its last earnings report?
Par Drugs and Chemicals Limited reported an EPS of ₹3.83 in its last earnings report. Following the earnings report the stock price went down -0.398%.
Which hedge fund is a major shareholder of Par Drugs and Chemicals Limited?
Currently, no hedge funds are holding shares in IN:PAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Par Drugs and Chemicals Limited
Par Drugs and Chemicals Limited is an Indian enterprise that focuses on the creation, production, and sale of active pharmaceutical ingredients (APIs) and specialized chemicals. Its comprehensive product line features a diverse array of compounds, such as magnesium salts, dried aluminum hydroxide gel, sodium aluminum silicate, precipitated silica, magnesium silicate, colloidal silicon dioxide, sucralfate USP, as well as various amorphous and custom-blended formulations. The company also extends its market presence through international exports. Founded in 1982, Par Drugs and Chemicals Limited is headquartered in Vadodara, India.
Technical Analysis
Alpa Laboratories Limited
―
Bal Pharma Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
Brooks Laboratories Limited
―
Vivimed Labs Limited
―